This update: October 31, 2025

Change for the month of October: +16% after living expenses. Change for September was +21.7% after living expenses.

Number of holdings today: 11

Unrealized Gains/Losses on Oct 31: SLNO +5.5%; VLTLF +103.5%; MDNAF +2.7%; GLNG -3.85%; OCUL -5.22%; ROOT -9%; QURE +11.15%; DLO +2.71%; GOSS -8.33%; LUCD +15.29%; GLSI -23.82%

Next update: November 28, 2025

Note: September through December will be added to quarterly performance at the end of December. Iā€™m aligning with the fiscal year as I began my second start with investing in November 2024. In the meantime, you can view month-to-month portfolio/base changes after living expenses on this page.

Note: On mobile devices the best view of the table below is likely horizontal orientation.

Ticker Company Reason I'm Buying
SLNO Soleno Therapeutics Inc. First trade recently initiated. Vykat XR, from Soleno, is the first approved medication specifically addressing hyperphagia in PWS. Sales were off to a great start then two events brought the stock down. A short report later debunked. Followed very soon after by a patient death that was determined unrelated to Vykat XR. Script visibility and projections are showing the company is highly likely to beat consensus by a wide margin in this Q report. This is a strong buy and hold now. One of my favorite set-up types in biotech. Just recently entered but could turn into a long-term hold.
VLTLF LiberyStream Infrastructure Long-term holder. Previously Volt Lithium, LibertyStream is able to extract lithium from oil field brine, a waste product of oil drilling. This provides the opportunity for a second stream of income for oil companies and water treatment companies focused on extracting valuable resources from oilfield brine like LiberyStream's partner Wellspring Hydro. It also serves as a domestic supply of lithium for the US. The company has just recently completed the purchase of a small $2.5M chemistry set to convert their lithium chloride eluate to lithium carbonate, the finished product for the end user's requirements. We are waiting on JV announcement most likely with an oil company. The nearest competitor to VLTLF will require $1.5B and some years to construct their prototype whereas VLTLF is able to get going for just $50M and scale. JV announcement could be imminent.
MDNAF Medicenna Therapeutics Inc. Long-term holder and have traded profitably once before. Medicenna is in Phase 1/2 for their engineered IL2 in multiple cancer types both as a monotherapy and in combination with Keytruda. They have shown excellent monotherapy results, and the market has not yet seen combination data. It's been quiet for a bit, but the company just announced they will update with data on December 5 at an oncology conference. Will be very exciting to get this data. I believe this is an excellent candidate for large pharma to acquire. There are other drugs in the pipeline, but this is the one to watch.
GLNG Golar LNG Ltd. First trade recently initiated. Golar makes and charters floating LNG. The only public company of its kind in a space with high barriers to entry and very little competition. The market does not yet know how to value Golar, in my opinion. Golar has three chartered vessels currently that makes a $17B EBTIDA backlog of 20-year offtake contracts. And they're focused on plans for the fourth unit with a fifth to come very soon after. Each of those additional FLNG's could add another $20/share to the stock price. LNG prices are depressed and expected to continue as such until the end of the decade given the expansion of LNG supply being built up in the US. But Golar has competitive advantages given where they operate, near the intended destination, cutting costs significantly. And if commodity prices do rise, Golar stands to add to the backlog given their contracts come with commodity upside in 2 out of the now 3 cases.
OCUL Ocular Therapeutix Inc. First trade recently initiated. Ocular is about to announce Phase 3 results in wet AMD. This is widely expected to be successful in the biotech investor community, and I believe the market will soon be forced to rerate and factor in the massive TAM and peak sales estimates between 3-5B. We could see a 100% move or more on this data and expectations for approval. The market is beginning to factor in and will start to give more value to the rest of their pipeline after late-stage trials begin for those (soon). Interestingly, the C-suite is also incentivized to get the stock over $30/sh.
ROOT Root Inc. Have traded ROOT twice this year profitably. Root is auto insurance with a tech twist. Improving on all metrics and down recently on short sightedness. The company needs to make additional investments in AI and support and there will be a one-off expense this Q that will temporarily lower profitability. They sell direct and are growing into more states and also increasing channel/partnership sales through the likes of Carvana and Hyundai which should prove to be drivers for revenue. This quarter could still be a blow-out quarter and given the market's reaction due to short-term memory tendencies, the stock could fly on it. If not, this is a solid hold and potential double over the next 6-12 months, in my opinion.
DLO DLocal Ltd. Long-term holder and have traded DLO twice this year profitably. DLocal is the undisputed in cross border payments, particularly in emerging markets. They're growing and have a long runway. This is one of the lowest risk investments in the market, in my opinion. Solid management executing flawlessly and consistently. Integrations and major partnerships are announced on a rolling basis.
GOSS Gossamer Bio Inc. First trade recently initiated. Phase 3 results in PAH expected February 2026. Massive upside potential. This is a catalyst play for me so position size adjusted down for that. Assuming it succeeds, I'll be looking to load more shares then.
QURE UniQure Held QURE prior to Phase 3 results and averaged up after results were published. I then trimmed to reallocate capital. Phase 3 results announced for Huntington's Disease. This is likely to be a high-profile drug in 2026 for the Trump Administration to get behind. A Commissioner's National Priority Voucher from the FDA is possible and expected by some investors to speed up the review time considerably (2 months compared to standard 10). This could trade north of $100/sh in a matter of a few months.
LUCD Lucid Diagnostics Have traded LUCD for a loss once this year prior to their MoIDX Contractor Advisory Committee Meeting in September. Medicare approval for their esophageal cancer screener is expected before the end of 2025. Local coverage in 2025 followed by full coverage in early 2026. Plan is to add shares on local coverage news.
GLSI Greenwich LifeSciences Long-term holder. Greenwich is in registrational Phase 3 for preventing breast cancer recurrence. Huge success in previous trial. Results could be any day now up until likely mid-2026. 14 "events" are needed to bring the trial to an end. This could be a 1,000% gainer from here on positive results. CEO share purchases are consistent and high. A lot of skin in the game.